Hepatic venous pressure gradient measurement guiding nonselective beta‐blocker therapy in a patient with clinically significant portal hypertension

Clinically significant portal hypertension (CSPH), defined as a hepatic venous pressure gradient (HVPG) ≥ 10 mmHg, is an independent risk factor for decompensated events in patients with compensated cirrhosis. Currently, the Baveno VII consensus recommends using nonselective beta‐blockers to treat c...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Portal hypertension & cirrhosis (Print) Ročník 2; číslo 2; s. 105 - 108
Hlavní autoři: Wang, Kun, Tian, Minghui, Zhang, Linpeng, Liu, Shanghao, Guo, Xiaoqing, Ma, Jianzhong
Médium: Journal Article
Jazyk:angličtina
Vydáno: Nanjing John Wiley & Sons, Inc 01.06.2023
Wiley
Témata:
Abdomen
Antigens
Blood pressure
Case reports
Catheters
Clinical significance
Drug dosages
Heart rate
Hepatic venous pressure gradient
Hepatitis B
Hypertension
Liver cancer
Liver cirrhosis
Liver diseases
Medical imaging
Medical prognosis
Non‐selective beta‐blocker
Patients
Pharmacists
Portal hypertension
Veins & arteries
ISSN:2770-5846, 2770-5838, 2770-5846
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Clinically significant portal hypertension (CSPH), defined as a hepatic venous pressure gradient (HVPG) ≥ 10 mmHg, is an independent risk factor for decompensated events in patients with compensated cirrhosis. Currently, the Baveno VII consensus recommends using nonselective beta‐blockers to treat compensated cirrhosis in patients with CSPH. Here, we report a unusual case of compensated cirrhosis with CSPH caused by hepatitis B, and we successfully adjust NSBBs drug treatment strategies monitoring by HVPG results and achieve response standards. Timely adjustment of NSBBs drug treatment strategies based on HVPG test results for patients with CSPH can improve the final response rate. Key points Timely adjustment of NSBBs drug treatment strategies for patients with CSPH based on HVPG test results can improve the final response rate. What this study adds? Early screening, diagnosis, and treatment can be achieved to ultimately improve the prognosis of patients with CSPH cirrhosis.
Bibliografie:Managing Editor: Ningning Wang
ObjectType-Case Study-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Report-1
ISSN:2770-5846
2770-5838
2770-5846
DOI:10.1002/poh2.47